Abstract 4357776: Prediction of major adverse clinical events using fatty liver index in patients following percutaneous coronary intervention

Introduction: Fatty liver is recognized as a risk factor for cardiovascular disease, and its severity can be assessed using the fatty liver index (FLI), a non-invasive marker calculated from body mass index, waist circumference, triglyceride, and gamma-glutamyl transferase levels. Despite its clinical utility, the association between FLI and long-term outcomes after percutaneous coronary intervention (PCI) remains unclear. Research Question: This study aimed to investigate whether FLI is associated with adverse clinical events, including all-cause death and repeat revascularization (RR), in patients undergoing PCI. Methods: We analyzed data from 576 patients who underwent PCI at a single center, enrolled in a prospective cohort registry. Patients were divided into four groups according to FLI quartiles (Q1–Q4). The primary endpoint was the 5-year cumulative incidence of all-cause death and repeat revascularization (RR), including myocardial infarction and ischemia-driven revascularization. Results: During the 5-year follow-up, 48 patients died (8.3%), and 58 experienced RR (10%). The incidence of all-cause death was significantly higher in Q1 (15%) compared with Q2 (7.7%), Q3 (7.0%), and Q4 (3.5%) (log-rank p=0.04, 0.03, and <0.01, respectively) (Figure 1). Multivariate Cox regression analysis showed that a higher FLI was associated with a lower risk of all-cause death (adjusted hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.97–0.99; p=0.03). In contrast, the incidence of RR was significantly higher in Q4 (19.7%) than in Q1 (3.6%), Q2 (7.3%), and Q3 (10.8%) (log-rank p<0.01, <0.01, and =0.04, respectively) (Figure 2). Multivariate analysis showed that a higher FLI was associated with a higher risk of RR (adjusted HR, 1.02; 95% CI, 1.01–1.03; p<0.01). Conclusions: A low FLI was associated with higher all-cause mortality, while a high FLI was associated with increased risk of repeat revascularization. These findings suggest that FLI reflects different aspects of clinical risk after PCI, and its assessment may be useful for predicting long-term outcomes in this population.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4357776
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4357776: Prediction of major adverse clinical events using fatty liver index in patients following percutaneous coronary intervention

Kunio Omori, Toru Yoshizaki, Takeo Horikoshi, Akira Sato et al.
Circulation
Liver Disease Diagnosis and Treatment
article

Abstract 4357776: Prediction of major adverse clinical events using fatty liver index in patients following percutaneous coronary intervention

Kunio Omori, Toru Yoshizaki, Takeo Horikoshi, Akira Sato, Takamitsu Nakamura, Tsuyoshi Kobayashi, Miu Eguchi
article en

Abstract

Introduction: Fatty liver is recognized as a risk factor for cardiovascular disease, and its severity can be assessed using the fatty liver index (FLI), a non-invasive marker calculated from body mass index, waist circumference, triglyceride, and gamma-glutamyl transferase levels. Despite its clinical utility, the association between FLI and long-term outcomes after percutaneous coronary intervention (PCI) remains unclear. Research Question: This study aimed to investigate whether FLI is associated with adverse clinical events, including all-cause death and repeat revascularization (RR), in patients undergoing PCI. Methods: We analyzed data from 576 patients who underwent PCI at a single center, enrolled in a prospective cohort registry. Patients were divided into four groups according to FLI quartiles (Q1–Q4). The primary endpoint was the 5-year cumulative incidence of all-cause death and repeat revascularization (RR), including myocardial infarction and ischemia-driven revascularization. Results: During the 5-year follow-up, 48 patients died (8.3%), and 58 experienced RR (10%). The incidence of all-cause death was significantly higher in Q1 (15%) compared with Q2 (7.7%), Q3 (7.0%), and Q4 (3.5%) (log-rank p=0.04, 0.03, and <0.01, respectively) (Figure 1). Multivariate Cox regression analysis showed that a higher FLI was associated with a lower risk of all-cause death (adjusted hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.97–0.99; p=0.03). In contrast, the incidence of RR was significantly higher in Q4 (19.7%) than in Q1 (3.6%), Q2 (7.3%), and Q3 (10.8%) (log-rank p<0.01, <0.01, and =0.04, respectively) (Figure 2). Multivariate analysis showed that a higher FLI was associated with a higher risk of RR (adjusted HR, 1.02; 95% CI, 1.01–1.03; p<0.01). Conclusions: A low FLI was associated with higher all-cause mortality, while a high FLI was associated with increased risk of repeat revascularization. These findings suggest that FLI reflects different aspects of clinical risk after PCI, and its assessment may be useful for predicting long-term outcomes in this population.

CirculationVol. 152(Suppl_3)
University of Yamanashi (JP)
Openalex Percentile: Top 57%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.